Skip to Content

Tag: Sleep Apnea


Anuja Bandyopadhyay

Specialty Providers

Q&A: Unlocking the ‘black box’ of AI technology

June 14, 2024Theresa Flaherty, Managing Editor

DARIEN, Ill. – As recently as four or five years ago, sleep medicine professionals were skeptical about the possibilities of artificial intelligence, but as they become more educated on the technology, they are seeing the possibilities it offers, says Dr. Anuja Bandyopadhyay.  “Once you start seeing beyond the black box and once people started realizing, ‘OK, this can be beneficial, it’s helping me save time, helping me save resources, improving access to care,’...

American Academy of Sleep Medicine (AASM), Anuja Bandyopadhyay, Artificial Intelligence (AI), Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Signifier gets large order

June 12, 2024HME News Staff

BOSTON – Signifier Medical Technologies has received a “milestone” order of 10,000 units of its eXciteOSA device, placed by Spectrum Sleep Solutions. This significant order comes on the back of South Carolina’s Human and Health Services Medicaid coverage for eXciteOSA, signaling a major step toward expanded accessibility and treatment for sleep apnea sufferers. The device uses neuromuscular electrical stimulation to move the upper airway muscles, working the intrinsic and...

eXciteOSA, Signifier Medical Technologies, Sleep Apnea


Read Full Articlered right arrow icon

News

ProSomnus seeks ‘renewed foundation’

May 15, 2024HME News Staff

PLEASANTON, Calif. – ProSomnus, which makes a CPAP alternative for the treatment of obstructive sleep apnea, has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware, listing more than $26.3 million in assets and $52.89 million in debts.  In connection with this process, ProSomnus has secured the support of multiple key investors and lenders under a plan that is designed to deliver an aggregate of approximately $20 million of new capital into the...

ProSomnus, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

New weight loss drug reduces AHI in certain patients

April 17, 2024HME News Staff

INDIANAPOLIS – Eli Lilly and Company’s tirzepatide injection diabetes and weight loss drug may help reduce AHI in patients with sleep apnea, according to the results of the company’s phase 3 clinical trials. The Surmount-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on PAP therapy for 52 weeks. Tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events...

Sleep Apnea, Tirzepatide, weight loss drugs


Read Full Articlered right arrow icon

Also Noted

Signifier’s CPAP alternative greenlighted by SC Medicaid 

April 8, 2024HME News Staff

BOSTON – Signifier Medical Technologies has announced that its eXciteOSA therapy for sleep-disordered breathing is now covered by South Carolina’s Health Connections Medicaid program. This coverage opens new doors for patients 18 and older who have previously had limited access to advanced treatments for obstructive sleep apnea. "We are thrilled that eXciteOSA is now covered by Medicaid in South Carolina," states Akhil Tripathi, director and co-founder of Signifier. "This...

CPAP Alternative, eXciteOSA, Signifier Medical Technologies, Sleep Apnea


Read Full Articlered right arrow icon

News

ResMed assesses sleep landscape 

March 18, 2024HME News Staff

SAN DIEGO – Fifty-seven percent of respondents say they are aware of sleep apnea, but only 26% of them have been diagnosed with the condition, according to ResMed’s 2024 Global Sleep Survey.  People are becoming more curious about how they sleep, the survey found, with 36% of respondents tracking their sleep either through a smartphone app (44%) or wearable (31%).  “With sleep being the third pillar of health, alongside diet and exercise, prioritizing your sleep...

2024, Global Sleep Survey, ResMed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Samsung expects to launch sleep apnea feature in Q3 

February 12, 2024HME News Staff

RIDGEFIELD PARK, N.J. – Samsung Electronics has announced that the sleep apnea feature on the Samsung Health Monitor app has received de novo authorization from the U.S. Food and Drug Administration. This feature, which detects signs of sleep apnea using a compatible Samsung Galaxy Watch and phone, was the first of its kind to be authorized by the FDA, the company says, following previous approval by Korea’s Ministry of Food and Drug Safety in October. “With the sleep apnea feature,...

App, Samsung, Sleep Apnea


Read Full Articlered right arrow icon

newspoll

News

Industry weighs potential impact of weight loss drugs

November 17, 2023Theresa Flaherty, Managing Editor

YARMOUTH, Maine – Respondents to a recent HME Newspoll aren’t quite sure what to make of the weight loss drug craze and whether or not it will impact demand for certain HME.  Nearly 40% of respondents say the drugs, which are known as GLP-1s and which include brand names like Ozempic and Wegovy, could reduce demand for CPAP devices, as obesity is among the most important risk factors for sleep apnea.  “Over time, I think this will have a huge impact on PAP devices...

Diabetes, Sleep Apnea, weight loss drugs


Read Full Articlered right arrow icon

Providers

Vivos announces deal with Lincare

October 25, 2023HME News Staff

LITTLETON, Colo. – Vivos Therapeutics, a medical technology company that makes oral appliances for patients suffering from mild-to-moderate obstructive sleep apnea and snoring in adults, has signed a distribution agreement with Lincare.  The agreement follows a successful a distribution pilot with Lincare and marks an important milestone in Vivos’ strategy to engage with leading durable medical equipment companies in the United States. Lincare will have a six-month exclusive deal...

Lincare, Oral appliance, Sleep Apnea, Vivos


Read Full Articlered right arrow icon

Also Noted

Vivos appliance gets clinical trial

October 12, 2023HME News Staff

LITTLETON, Colo. – Vivos Therapeutics, a medical technology company focused on developing treatments for patients suffering from mild-to-moderate obstructive sleep apnea and snoring in adults, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine. “We are extremely excited to be starting this trial at Stanford Medicine, which has been in the works for some time” said R. Kirk Huntsman, chairman and CEO of Vivos. “I...

Sleep Apnea, Vivos


Read Full Articlered right arrow icon